Abstract
The authors believe that cyclooxygenase-2 (COX-2) inhibitors, in particular at higher dosages and for longer-term use, should not be a first-line therapy for patients who can tolerate alternative t...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have